SCHEMBL1425396

SCHEMBL1425396

C1=CC[C@H]2CNC[C@H]2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2113163 1.00
SCHEMBL20748212 1.00
SCHEMBL12620801 0.84 CCR5 (0.38)
SCHEMBL4871844 0.80 CCR5 (0.33)
SCHEMBL4531955 0.79
SCHEMBL2244194 0.79
SCHEMBL418167 0.74
SCHEMBL14096697 0.74
SCHEMBL416052 0.74
SCHEMBL260537 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 US disclosed
EP-4490152-A1 ACTIVATORS OF EFFECTOR T CELLS Orum Therapeutics Inc. (KR) 2025-01-15 EP disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 WO disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 WO disclosed
US-20230012073-A1 SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B CADENT THERAPEUTICS, INC. (US) 2023-01-12 US disclosed
US-11116749-B2 Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B CADENT THERAPEUTICS, INC (US) 2021-09-14 US disclosed
US-10981887-B2 Benzothiophene estrogen receptor modulators G1 THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-10787453-B2 Octahydropyrrolopyrroles their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-09-29 US disclosed
US-10787453-B2 Octahydropyrrolopyrroles their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-09-29 US disclosed
US-20200216406-A1 BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS G1 THERAPEUTICS, INC. (US) 2020-07-09 US disclosed
US-20040044029-A1 Azabicyclic compounds are central nervous system active agents ABBOTT LABORATORIES 2004-03-04 US disclosed
WO-2004016604-A2 AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS ABBOTT LABORATORIES (US) 2004-02-26 WO disclosed
EP-1061076-A1 N-ACYL CYCLIC AMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2000-12-20 EP disclosed
US-6140333-A FOR TREATMENT AND/OR PROPHYLAXIS OF DISEASES INCLUDE SUCH RESPIRATORY DISEASES AS CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EMPHYSEMA BANYU PHARMACEUTICAL CO LTD (JP) 2000-10-31 US disclosed
EP-0507534-B1 Succinic acid compounds KISSEI PHARMACEUTICAL (JP) 1996-02-28 EP disclosed
US-5409929-A Treating psychosis, dyskinesia THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1995-04-25 US disclosed
WO-1993016047-A1 HYDROISOINDOLINES AND HYDROISOQUINOLINES AS PSYCHOTROPIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-08-19 WO disclosed
US-5216018-A Antidyskinetic agents DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-06-01 US disclosed
US-5202335-A Hypoglycemic, antidiabetic agents KISSEI PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0507534-A1 Succinic acid compounds KISSEI PHARMACEUTICAL CO., LTD. (JP) 1992-10-07 EP disclosed